6.5 C
New York
Tuesday, January 25, 2022

An antibody COVID-19 cannot evade

Must Read

Fatigue could be an early indicator for early death

How tired various activities make an elderly person feel can foretell whether or not death is less...

Study finds a link between male anxiety and serious illness

Risk factors for cardiovascular disease and diabetes occur early in the lives of anxious men.

Ischemic Stroke Hits Young Women Harder Than Young Men

Females under 35 have a 44% higher risk of Ischemic Stroke than males A...
Manish Saini
Manish works as a Journalist and writer at Revyuh.com. He has studied Political Science and graduated from Delhi University. He is a Political engineer, fascinated by politics, and traditional businesses. He is also attached to many NGO's in the country and helping poor children to get the basic education. Email: Manish (at) revyuh (dot) com

S2K146 defends against coronavirus and its mutations, and it’s a good candidate for developing anti-infection drugs.

American researchers have found an antibody that neutralizes a wide range of sarbecoviruses, including SARS-CoV-2 and its variants.

The study published in the journal Science was carried out by researchers from the University of Washington in Seattle and Humabs Biomed SA.

The S2K146 antibody was extracted from the B cells of a COVID-19 survivor. It targets the viral spike protein, like other antibodies generated by SARS-CoV-2 vaccines, and effectively protects against infection.

Experiments on Syrian hamsters revealed that S2K146 totally inhibited viral multiplication in the lungs.

“S2K146 mimics the molecular contacts formed with the ACE2 receptor by binding exactly where the spike protein needs to attach to the cell,” said the authors.

According to the study’s authors, it will be extremely difficult for future SARS-CoV-2 mutations to escape S2K146 and remain alive.

Only one form of the coronavirus was found to be immune to the antibody, but it had a limited ability to infect cells.

“Our findings suggest it’s a very good candidate for clinical development as monoclonal antibody treatment,” said study leader David Veesler, associate professor of biochemistry at the University of Washington School of Medicine.

Source: 10.1126/science.abm8143

Image Credit: Getty

You were reading: An antibody COVID-19 cannot evade or escape

- Advertisement -
- Advertisement -

Latest News

- Advertisement -

More Articles Like This

- Advertisement -